Ranbaxy laboratories today launched a new antimalarial drug Synriam to treat malaria caused by plasmodium falciparum parasite. The drug will treat uncomplicated malaria. The research which took place for nine years was partly supported by the Indian government. Clinical trials in India Tanzania and Thailand have suggested that the drug has an amazing 95% cure rate and could serve as alternative to existing anti-malarial therapy. Senior Ranbaxy officials announced today that the drug would be made available in India at Rs 130 for three tablets and treatment would involve taking a single tablet for three days. Almost 77 percent of
